SREBF2 and cancer: SREBP-2 and its regulated enzymes from the mevalonate pathway, including HMGCR, FPPS, SQS, and DHCR4, participate in the progression of various cancers including prostate, breast, lung, and hepatocellular cancer, and thus are important potential therapeutic targets.